Antibody variable domains targeting the NKG2D receptor
Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
1. A method of providing a cancer immunotherapy for treating a cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of a protein comprising an antigen-binding site that binds NKG2D and an additional antigen-binding site that binds a tumor-associated antigen expressed by the cancer,
wherein the antigen-binding site that binds NKG2D comprises:
an antibody heavy chain variable domain comprising a complementarity-determining region 1 (CDR1) amino acid sequence of SEQ ID NO: 48, a complementarity-determining region 2 (CDR2) amino acid sequence of SEQ ID NO: 30, and a complementarity-determining region 3 (CDR3) amino acid sequence of SEQ ID NO: 78, 74, 76, 80, or 82; and
an antibody light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO: 32, a CDR2 amino acid sequence of SEQ ID NO: 33, and a CDR3 amino acid sequence of SEQ ID NO: 34,
wherein the additional antigen-binding site comprises an antibody heavy chain variable domain,
wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D is present on a first polypeptide that further comprises a first antibody constant region, and the antibody heavy chain variable domain of the additional antigen-binding site is present on a second polypeptide that further comprises a second antibody constant region, and
wherein the first antibody constant region and the second antibody constant region form a complex that binds CD16.
2. The method of claim 1 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 48, 30, and 78, respectively, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively.
3. The method of claim 2 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 85, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 8.
4. The method of claim 2 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises the amino acid sequence of SEQ ID NO: 85, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises the amino acid sequence of SEQ ID NO: 8.
5. The method of claim 1 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 48, 30, and 74, respectively, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively.
6. The method of claim 5 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 83, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 8.
7. The method of claim 1 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 48, 30, and 76, respectively, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively.
8. The method of claim 7 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 84, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 8.
9. The method of claim 1 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 48, 30, and 80, respectively, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively.
10. The method of claim 9 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 86, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 8.
11. The method of claim 1 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 48, 30, and 82, respectively, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NOs: 32, 33, and 34, respectively.
12. The method of claim 11 , wherein the antibody heavy chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 41, and the antibody light chain variable domain of the antigen-binding site that binds NKG2D comprises an amino acid sequence at least 95% identical to SEQ ID NO: 8.
13. The method of claim 1 , wherein the first antibody constant region and the second antibody constant region each comprise hinge, CH2, and CH3 domains.
14. The method of claim 1 , wherein the first antibody constant region and the second antibody constant region are human IgG1 Fc regions.
15. The method of claim 14 , wherein the first antibody constant region comprises a Y349C substitution and the second antibody constant region comprises an S354C substitution, numbered according to the EU index as in Kabat.
16. The method of claim 14 , wherein the first antibody constant region comprises K360E and K409W substitutions, and the second antibody constant region comprises Q347R, D399V and F405T substitutions, numbered according to the EU index as in Kabat.